[HTML][HTML] ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious …
Background The present review is part of the ESCMID Study Group for Infections in
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and …
Consensus position statement on advancing the standardised reporting of infection events in immunocompromised patients
BW Teh, M Mikulska, D Averbuch… - The Lancet Infectious …, 2024 - thelancet.com
Patients can be immunocompromised from a diverse range of disease and treatment factors,
including malignancies, autoimmune disorders and their treatments, and organ and stem …
including malignancies, autoimmune disorders and their treatments, and organ and stem …
Risk and outcome of breakthrough COVID-19 infections in vaccinated patients with cancer: real-world evidence from the national COVID cohort collaborative
Q Song, B Bates, YR Shao, FC Hsu, F Liu… - Journal of Clinical …, 2022 - ascopubs.org
PURPOSE To provide real-world evidence on risks and outcomes of breakthrough COVID-
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
19 infections in vaccinated patients with cancer using the largest national cohort of COVID …
Infectious complications and NK cell depletion following daratumumab treatment of multiple myeloma
Treatment with Daratumumab (Dara), a monoclonal anti-CD38 antibody of IgG1 subtype, is
effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular …
effective in patients with multiple myeloma (MM). However, Dara also impairs the cellular …
Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working …
L Henze, C Buhl, M Sandherr, OA Cornely… - Annals of …, 2022 - Springer
Clinical reactivations of herpes simplex virus or varicella zoster virus occur frequently among
patients with malignancies and manifest particularly as herpes simplex stomatitis in patients …
patients with malignancies and manifest particularly as herpes simplex stomatitis in patients …
Multiple myeloma in the time of COVID-19
AS Al Saleh, T Sher, MA Gertz - Acta haematologica, 2020 - karger.com
We provide our recommendations (not evidence based) for managing multiple myeloma
patients during the pandemic of COVID-19. We do not recommend therapy for smoldering …
patients during the pandemic of COVID-19. We do not recommend therapy for smoldering …
Predictors of early morbidity and mortality in newly diagnosed multiple myeloma: data from five randomized, controlled, phase III trials in 3700 patients
EK Mai, T Hielscher, U Bertsch, HJ Salwender… - Leukemia, 2024 - nature.com
Early morbidity and mortality affect patient outcomes in multiple myeloma. Thus, we
dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for …
dissected the incidence and causes of morbidity/mortality during induction therapy (IT) for …
Inflammation and infection in plasma cell disorders: how pathogens shape the fate of patients
J Caro, M Braunstein, L Williams, B Bruno… - Leukemia, 2022 - nature.com
The role of infection and chronic inflammation in plasma cell disorders (PCD) has been well-
described. Despite not being a diagnostic criterion, infection is a common complication of …
described. Despite not being a diagnostic criterion, infection is a common complication of …
A predictive model for risk of early grade≥ 3 infection in patients with multiple myeloma not eligible for transplant: analysis of the FIRST trial
C Dumontet, C Hulin, MA Dimopoulos, A Belch… - Leukemia, 2018 - nature.com
Infections are a major cause of death in patients with multiple myeloma. A post hoc analysis
of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections …
of the phase 3 FIRST trial was conducted to characterize treatment-emergent (TE) infections …
Targeting NF-κB signaling for multiple myeloma
Multiple myeloma (MM) is the second most common hematologic malignancy in the world.
Even though survival rates have significantly risen over the past years, MM remains …
Even though survival rates have significantly risen over the past years, MM remains …